{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:58:16Z","timestamp":1792123096825,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12328-025-02126-x","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T14:59:19Z","timestamp":1745593159000},"page":"463-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Relapsed refractory immune checkpoint inhibitor-induced colitis treated with tacrolimus and maintained with vedolizumab"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-7327","authenticated-orcid":false,"given":"Shohei","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Shimaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Fujimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takato","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Hanabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Numao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"2126_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson D. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J for ImmunoTherapy of Cancer. 2019;7:306.","journal-title":"J for ImmunoTherapy of Cancer"},{"key":"2126_CR2","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"B Schneider","year":"2021","unstructured":"Schneider B, Naidoo J, Santomasso B, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2126_CR3","first-page":"230","volume":"18","author":"J Thompson","year":"2020","unstructured":"Thompson J, Schneider B, Brahmer J, et al. Management of immunotherapy-related toxicities version 1.2020, featured updatets to the NCCN Guidelines. JNCCN.org. 2020;18(3):230\u201341.","journal-title":"JNCCN.org."},{"issue":"5","key":"2126_CR4","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1177\/1078155218793709","volume":"25","author":"T Beardslee","year":"2019","unstructured":"Beardslee T, Draper A, Kudchadkar R, et al. Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor \u03b1 -therapy. J Onc Pharm Pract. 2019;25(5):1275\u201381.","journal-title":"J Onc Pharm Pract"},{"key":"2126_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/healthcare9040418","volume":"9","author":"Y Kunogi","year":"2021","unstructured":"Kunogi Y, Tominaga K, Abe K, et al. Refractory immune checkpoint inhibitor-induced colitis improved by tacrolimus: a case report. Healthcare. 2021;9:418.","journal-title":"Healthcare"},{"key":"2126_CR6","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.cgh.2020.01.033","volume":"18","author":"M Collins","year":"2020","unstructured":"Collins M, Soularue E, Carbonnel F. Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review. Clin Gastroenterol Hepatol. 2020;18:1393\u2013403.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"30","key":"2126_CR7","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1200\/JCO.19.00320","volume":"37","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Ali FS, Naqash AR, et al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J of Clinic Oncol. 2019;37(30):2738\u201345.","journal-title":"J of Clinic Oncol"},{"key":"2126_CR8","doi-asserted-by":"publisher","first-page":"e00946","DOI":"10.14309\/crj.0000000000000946","volume":"9","author":"G Nogal","year":"2022","unstructured":"Nogal G, Patel N. Refractory checkpoint inhibitor colitis responsive to Ustekinumab. ACG Case Rep J. 2022;9:e00946.","journal-title":"ACG Case Rep J"},{"issue":"1","key":"2126_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/CMR.0000000000000543","volume":"29","author":"R Mir","year":"2019","unstructured":"Mir R, Shaw HM, Nathan PD. Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis. Melanoma Res. 2019;29(1):102\u20136.","journal-title":"Melanoma Res"},{"key":"2126_CR10","first-page":"2056","volume":"67","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Alsaadi D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer. 2018;67:2056\u201367.","journal-title":"J Immunother Cancer"},{"key":"2126_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-023-01887-7","author":"H Ishihara","year":"2023","unstructured":"Ishihara H, Watanabe T, Kumei S, et al. A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte-monocyte apheresis combination therapy. Clin J of Gastroenterol. 2023. https:\/\/doi.org\/10.1007\/s12328-023-01887-7.","journal-title":"Clin J of Gastroenterol"},{"key":"2126_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","volume":"29","author":"R Venkataramanan","year":"1995","unstructured":"Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmaco. 1995;29:404\u201330.","journal-title":"Clin Pharmaco"},{"key":"2126_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12531","author":"E Zhang","year":"2021","unstructured":"Zhang E, Kiely C, Sandanayake N, et al. Calcineurin inhibitors in steroid and anti-TNF-alpha refractory immune checkpoint inhibitor colitis. JGH Open. 2021. https:\/\/doi.org\/10.1002\/jgh3.12531.","journal-title":"JGH Open."},{"key":"2126_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S2468-1253(20)30014-5","volume":"5","author":"N Powell","year":"2020","unstructured":"Powell N, Ibraheim H, Raine T, et al. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol. 2020;5:679\u201397.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2126_CR15","doi-asserted-by":"publisher","first-page":"9566","DOI":"10.1200\/JCO.2017.35.15_suppl.9566","volume":"35","author":"DY Wang","year":"2017","unstructured":"Wang DY, Kim DW, Shah NJ, et al. Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy(MONO) and combination PD-1\/CTLA-4 inhibitors(COMBO) in melanoma. Proc Am Soc Clin Oncol. 2017;35:9566.","journal-title":"Proc Am Soc Clin Oncol."},{"key":"2126_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/25785826.2019.1580477","volume":"42","author":"H Kikuchi","year":"2019","unstructured":"Kikuchi H, Sakuraba H, Akemoto Y, et al. A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine. Immunol Med. 2019;42:39\u201344.","journal-title":"Immunol Med"},{"issue":"3","key":"2126_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.cgh.2018.04.060","volume":"17","author":"B Christensen","year":"2019","unstructured":"Christensen B, Gibson P, Micic D, et al. Effectiveness of calcineurin inhibitors with vedolizumab in refractory inflammatory bowel disease. Clin Gastroenterol Hepatol. 2019;17(3):486\u201393.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02126-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-025-02126-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02126-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:28:52Z","timestamp":1747826932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-025-02126-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2126"],"URL":"https:\/\/doi.org\/10.1007\/s12328-025-02126-x","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures have been performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/animal rights"}},{"value":"Informed consent was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}